Efficacy of rosuvastatin for the treatment of nonalcoholic steatohepatitis with hyperlipidemia

Efficacy of rosuvastatin for the treatment of nonalcoholic steatohepatitis with hyperlipidemia - Effect of rosuvastatin on NAFLD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000000717

Enrollment

Registered

2007-06-01

Start date

2007-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.NAFLD with hypercholesterolemia

Exclusion criteria

Exclusion criteria: 1.patient with previous administration of rosuvastatin 2.patient with other origin of hepatitis than NASH 3.patient with allergy for rosuvastatin 4.patient with severe liver damage or obstructive biliary disease 5.patient recieving cyclosporin. 6. pregnancy

Design outcomes

Primary

Measure	Time frame
liver transaminases	—

Secondary

Measure	Time frame
1.liver histology, 2.adipocytokines,3.liver fibrosis marker,4.glucose metabolism	—

Countries

Japan

Contacts

Public ContactHideyuki Hyogo

Graduate School of Biomedical Sciences, Hiroshima University. Department of Medicine and Molecular Science

hidehyogo@aol.com082-257-5190

Outcome results